儿童炎症性肠病的研究现状及展望

doi:10.12372/jcp.2023.23e0957

摘要/Abstract

摘要：

儿童炎症性肠病（PIBD）是一组病因不明的慢性复发性非特异性肠道炎症性疾病，发病机制复杂，目前在诊断和治疗方面仍然面临挑战。近年来，儿童IBD在国内外的发病率呈现上升趋势，引起了儿科医师的广泛关注。文章在儿童IBD发病机制进展、最佳治疗目标的监测策略、治疗方法进展、青春期IBD管理及向成人转诊过渡衔接等方面进行了总结，旨在为我国儿科医师IBD的研究提供参考。

关键词: 儿童, 炎症性肠病, 发病机制, 达标治疗, 青春期转诊过渡

Abstract:

Pediatric inflammatory bowel disease (PIBD) refers to a group of chronic and recurrent intestinal inflammatory diseases with unidentified cause. The complexity of its pathogenesis presents ongoing challenges in diagnosis and treatment. In recent years, there has been a noticeable increase in the prevalence of IBD among children both domestically and internationally, which has aroused widespread concern among pediatricians. This article aims to provide a comprehensive overview of the pathogenesis in pediatric IBD, a turbo-charged treat to target strategy in IBD, as well as the transition of management in adolescents with IBD. Its findings can serve as a valuable reference for Chinese pediatricians engaged in IBD research.

Key words: pediatric, inflammatory bowel disease, pathogenesis, treat to target, transition of management

吴捷, 张添卓. 儿童炎症性肠病的研究现状及展望[J]. 临床儿科杂志, 2023, 41(11): 801-807.

WU Jie, ZHANG Tianzhuo. An analysis of the present status and future prospects of pediatric inflammatory bowel disease[J]. Journal of Clinical Pediatrics, 2023, 41(11): 801-807.

参考文献 49

[1]	Ruemmele FM, Veres G, Kolho KL, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease[J]. J Crohns Colitis, 2014, 8(10): 1179-1207. doi: 10.1016/j.crohns.2014.04.005 pmid: 24909831
[2]	Turner D, Ruemmele FM, Orlanski-Meyer E, et al. Management of paediatric ulcerative colitis, part 1: ambulatory care-an evidence-based guideline from European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition[J]. J Pediatr Gastroenterol Nutr, 2018, 67(2): 257-291. doi: 10.1097/MPG.0000000000002035
[3]	Birimberg-Schwartz L, Zucker DM, Akriv A, et al. Development and validation of diagnostic criteria for IBD subtypes including IBD-unclassified in children: a multicentre study from the pediatric IBD Porto group of ESPGHAN[J]. J Crohns Colitis, 2017, 11(9): 1078-1084. doi: 10.1093/ecco-jcc/jjx053 pmid: 28430891
[4]	Benchimol EI, Fortinsky KJ, Gozdyra P, et al. Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends[J]. Inflamm Bowel Dis, 2011, 17(1): 423-439. doi: 10.1002/ibd.21349 pmid: 20564651
[5]	Kuenzig ME, Fung SG, Marderfeld L, et al. Twenty-first century trends in the global epidemiology of pediatric-onset inflammatory bowel disease: systematic review[J]. Gastroenterology, 2022, 162(4): 1147-1159. doi: 10.1053/j.gastro.2021.12.282 pmid: 34995526
[6]	Windsor JW, Buie M, Coward S, et al. A28 relative rates of ulcerative colitis to Crohn’s disease: parallel epidemiologies in newly vs. highly industrialized countries[J]. Journal of the Canadian Association of Gastroenterology, 2020, 3(Supplement_1): 34-35.
[7]	Kugathasan S, Baldassano RN, Bradfield JP, et al. Loci on 20q13 and 21q22 are associated with pediatric-onset inflammatory bowel disease[J]. Nat Genet, 2008, 40(10): 1211-1215. doi: 10.1038/ng.203 pmid: 18758464
[8]	Muise AM, Snapper SB, Kugathasan S. The age of gene discovery in very early onset inflammatory bowel disease[J]. Gastroenterology, 2012, 143(2): 285-288. doi: 10.1053/j.gastro.2012.06.025 pmid: 22727850
[9]	Bequet E, Sarter H, Fumery M, et al. Incidence and phenotype at diagnosis of very-early-onset compared with later-onset paediatric inflammatory bowel disease: a population-based study [1988-2011][J]. J Crohns Colitis, 2017, 11(5): 519-526. doi: 10.1093/ecco-jcc/jjw194 pmid: 28453757
[10]	Ong C, Aw MM, Liwanag MJ, et al. Rapid rise in the incidence and clinical characteristics of pediatric inflammatory bowel disease in a South-East Asian cohort in Singapore, 1994-2015[J]. J Dig Dis, 2018, 19(7): 395-403. doi: 10.1111/cdd.2018.19.issue-7
[11]	Turpin W, Goethel A, Bedrani L, et al. Determinants of IBD heritability: genes, bugs, and more[J]. Inflamm Bowel Dis, 2018, 24(6): 1133-1148. doi: 10.1093/ibd/izy085 pmid: 29701818
[12]	Suarez RG, Osornio-Vargas AR, Wine E. Ambient air pollution and pediatric inflammatory bowel diseases: an updated scoping review[J]. Dig Dis Sci, 2022, 67(9): 4342-4354. doi: 10.1007/s10620-022-07597-3
[13]	Forbes JD, Van Domselaar G, Bernstein CN. Microbiome survey of the inflamed and noninflamed gut at different compartments within the gastrointestinal tract of inflammatory bowel disease patients[J]. Inflamm Bowel Dis, 2016, 22(4): 817-825. doi: 10.1097/MIB.0000000000000684 pmid: 26937623
[14]	Parada Venegas D, De la Fuente MK, Landskron G, et al. Corrigendum: short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases[J]. Front Immunol, 2019, 10: 1486. doi: 10.3389/fimmu.2019.01486 pmid: 31316522
[15]	Di Vincenzo F, Puca P, Lopetuso LR, et al. Bile acid-related regulation of mucosal inflammation and intestinal motility: from pathogenesis to therapeutic application in IBD and microscopic colitis[J]. Nutrients, 2022, 14(13): 2664. doi: 10.3390/nu14132664
[16]	Kurilshikov A, Wijmenga C, Fu J, et al. Host genetics and gut microbiome: challenges and perspectives[J]. Trends Immunol, 2017, 38(9): 633-647. doi: S1471-4906(17)30106-0 pmid: 28669638
[17]	Flannigan KL, Geem D, Harusato A, et al. Intestinal antigen-presenting cells: key regulators of immune homeostasis and inflammation[J]. Am J Pathol, 2015, 185(7): 1809-1819. doi: 10.1016/j.ajpath.2015.02.024 pmid: 25976247
[18]	Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD[J]. Gastroenterology, 2021, 160(5): 1570-1583. doi: 10.1053/j.gastro.2020.12.031 pmid: 33359090
[19]	Plevris N, Lees CW. Disease monitoring in inflammatory bowel disease: evolving principles and possibilities[J]. Gastroenterology, 2022, 162(5): 1456-1475. doi: 10.1053/j.gastro.2022.01.024
[20]	Kuharic M, Krugliak Cleveland N, Candela N, et al. P042 Early versus later use of vedolizumab In IBD: patient characteristics and treatment patterns in the real world (RALEE)[J]. Am J Gastroenterol, 2021, 116(Suppl 1): S11. doi: 10.14309/01.ajg.0000798768.43978.95 pmid: 34848629
[21]	Feuerstein JD, Nguyen GC, Kupfer SS, et al. American gastroenterological association institute guideline on therapeutic drug monitoring in inflammatory bowel disease[J]. Gastroenterology, 2017, 153(3): 827-834. doi: S0016-5085(17)35963-2 pmid: 28780013
[22]	Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children[J]. Gastroenterology, 2007, 132(3): 863-873. doi: 10.1053/j.gastro.2006.12.003 pmid: 17324398
[23]	Hyams J, Damaraju L, Blank M, et al. Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis[J]. Clin Gastroenterol Hepatol, 2012, 10(4): 391-399. doi: 10.1016/j.cgh.2011.11.026
[24]	Papamichael K, Afif W, Drobne D, et al. Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives[J]. Lancet Gastroenterol Hepatol, 2022, 7(2): 171-185. doi: 10.1016/S2468-1253(21)00223-5
[25]	Vvan Rheenen PF, Aloi M, Assa A, et al. The medical management of paediatric Crohn's disease: an ECCO-ESPGHAN guideline update[J]. J Crohns Colitis, 2020-jjaa161.
[26]	Cheifetz AS, Abreu MT, Afif W, et al. A comprehensive literature review and expert consensus statement on therapeutic drug monitoring of biologics in inflammatory bowel disease[J]. Am J Gastroenterol, 2021, 116(10): 2014-2025. doi: 10.14309/ajg.0000000000001396 pmid: 34388143
[27]	Venkatesh K, Cohen M, Evans C, et al. Feasibility of confocal endomicroscopy in the diagnosis of pediatric gastrointestinal disorders[J]. World J Gastroenterol, 2009, 15(18): 2214-2219. doi: 10.3748/wjg.15.2214
[28]	Miele E, Shamir R, Aloi M, et al. Nutrition in pediatric inflammatory bowel disease: a position paper on behalf of the Porto inflammatory bowel disease group of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition[J]. J Pediatr Gastroenterol Nutr, 2018, 66(4): 687-708. doi: 10.1097/MPG.0000000000001896
[29]	Bischoff SC, Bager P, Escher J, et al. ESPEN guideline on clinical nutrition in inflammatory bowel disease[J]. Clin Nutr, 2023, 42(3): 352-379. doi: 10.1016/j.clnu.2022.12.004 pmid: 36739756
[30]	Sarbagili-Shabat C, Albenberg L, Van Limbergen J, et al. A novel UC exclusion diet and antibiotics for treatment of mild to moderate pediatric ulcerative colitis: a prospective open-label pilot study[J]. Nutrients, 2021, 13(11): 3736. doi: 10.3390/nu13113736
[31]	Radziszewska M, Smarkusz-Zarzecka J, Ostrowska L, et al. Nutrition and supplementation in ulcerative colitis[J]. Nutrients, 2022, 14(12): 2469. doi: 10.3390/nu14122469
[32]	Turner D, Ruemmele FM, Orlanski-Meyer E, et al. Management of paediatric ulcerative colitis, part 2: acute severe colitis-an evidence-based consensus guideline from the European Crohn's and Colitis Organization and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition[J]. J Pediatr Gastroenterol Nutr, 2018, 67(2): 292-310. doi: 10.1097/MPG.0000000000002036
[33]	Nakase H, Uchino M, Shinzaki S, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020[J]. J Gastroenterol, 2021, 56(6): 489-526. doi: 10.1007/s00535-021-01784-1 pmid: 33885977
[34]	Atia O, Shavit-Brunschwig Z, Mould DR, et al. Outcomes, dosing, and predictors of vedolizumab treatment in children with inflammatory bowel disease (VEDOKIDS): a prospective, multicentre cohort study[J]. Lancet Gastroenterol Hepatol, 2023, 8(1): 31-42. doi: 10.1016/S2468-1253(22)00307-7
[35]	Singh N, Rabizadeh S, Jossen J, et al. Multi-center experience of vedolizumab effectiveness in pediatric inflammatory bowel disease[J]. Inflamm Bowel Dis, 2016, 22(9): 2121-6. doi: 10.1097/MIB.0000000000000865 pmid: 27542130
[36]	Dayan JR, Dolinger M, Benkov K, et al. Real world experience with ustekinumab in children and young adults at a tertiary care pediatric inflammatory bowel disease center[J]. J Pediatr Gastroenterol Nutr, 2019, 69(1): 61-67. doi: 10.1097/MPG.0000000000002362
[37]	Wlazło M, Kierkuś J. Dual biologic therapy for the treatment of pediatric inflammatory bowel disease: a review of the literature[J]. J Clin Med, 2022, 11(7).
[38]	Panés J, Loftus EV, Higgins PDR, et al. Induction and maintenance treatment with upadacitinib improves health-related quality of life in patients with moderately to severely active ulcerative colitis: phase 3 study results[J]. Inflamm Bowel Dis, 2023, 29(9): 1421-1430. doi: 10.1093/ibd/izac260
[39]	D'Haens G, Panés J, Louis E, et al. Upadacitinib was efficacious and well-tolerated over 30 months in patients with Crohn's disease in the celest extension study[J]. Clin Gastroenterol Hepatol, 2022, 20(10): 2337-2346.. doi: 10.1016/j.cgh.2021.12.030
[40]	Collen LV. Rapid clinical remission with upadacitinib in a pediatric patient with refractory Crohn's disease[J]. Inflamm Bowel Dis, 2023, 29(7): 1175-1176. doi: 10.1093/ibd/izad048
[41]	Moore H, Dubes L, Fusillo S, et al. Tofacitinib therapy in children and young adults with pediatric-onset medically refractory inflammatory bowel disease[J]. J Pediatr Gastroenterol Nutr, 2021, 73(3): e57-e62. doi: 10.1097/MPG.0000000000003190
[42]	Kassam Z, Lee CH, Yuan Y, et al. Fecal microbiota transplantation for clostridium difficile infection: systematic review and meta-analysis[J]. Am J Gastroenterol, 2013, 108(4): 500-508. doi: 10.1038/ajg.2013.59 pmid: 23511459
[43]	黄瑛, 王玉环. 粪菌移植治疗儿童炎症性肠病[J]. 中华实用儿科临床杂志, 2017, 32(7): 491-493.
[44]	Tan P, Li X, Shen J, et al. Fecal microbiota transplantation for the treatment of inflammatory bowel disease: an update[J]. Front Pharmacol, 2020, 11: 574533. doi: 10.3389/fphar.2020.574533
[45]	Reider S, Binder L, Fürst S, et al. Hematopoietic stem cell transplantation in refractory Crohn's disease: should it be considered?[J]. Cells, 2022, 11(21): 3436. doi: 10.3390/cells11213436
[46]	Liang J, Zhang H, Wang D, et al. Allogeneic mesenchymal stem cell transplantation in seven patients with refractory inflammatory bowel disease[J]. Gut, 2012, 61(3): 468-469. doi: 10.1136/gutjnl-2011-300083 pmid: 21617158
[47]	Bollegala N, Brill H, Marshall JK. Resource utilization during pediatric to adult transfer of care in IBD[J]. J Crohns Colitis, 2013, 7(2): e55-60. doi: 10.1016/j.crohns.2012.05.010
[48]	Menon T, Afzali A. Inflammatory bowel disease: a practical path to transitioning from pediatric to adult care[J]. Am J Gastroenterol, 2019, 114(9): 1432-1440. doi: 10.14309/ajg.0000000000000222 pmid: 30985298
[49]	Sexton KA, Walker JR, Graff LA, et al. Evidence of bidirectional associations between perceived stress and symptom activity: a prospective longitudinal investigation in inflammatory bowel disease[J]. Inflamm Bowel Dis, 2017, 23(3): 473-483. doi: 10.1097/MIB.0000000000001040 pmid: 28221251